Building 1897
Seoul, 04516, South Korea
NCT Number: NCT07489183
A prospective, open, observational study to confirm the lipid-lowering effect, changes in glucose metabolism, and safety after 6 months of administration of atostazet to hypercholesterolemic patients 65 years of age or older
Looking for future studies?
Notify Me65 year and older
All sexes
Observational
Seoul, 04516, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 weeks to the base
Incidence of Adverse events
Looking for future studies?
Notify MeDong Wha Pharmaceutical Co. Ltd.
Industry
Acronym: DW-EAZ-OS01
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05362903
Arterial Occlusive Diseases, Arteriosclerosis
Freudenstadt, Baden-Wurttemberg, Germany
View Trial DetailsNCT05952856
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Daphne, Alabama, United States
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsNCT06822621
Body Weight, Dyslipidemias
Athens, Attica, Greece
View Trial Details